SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    R. S. K. Vijayan, Peng He, Vivek Modi, Krisna C. Duong-Ly, Haiching Ma, Jeffrey R. Peterson, Roland L. Dunbrack, Ronald M. Levy, Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors, Journal of Medicinal Chemistry, 2015, 58, 1, 466

    CrossRef

  2. 2
    Monika A. Davare, Cristina E. Tognon, Detecting and targetting oncogenic fusion proteins in the genomic era, Biology of the Cell, 2015, 107, 5
  3. 3
    Christal D. Sohl, Molly R. Ryan, BeiBei Luo, Kathleen M. Frey, Karen S. Anderson, Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles’ Heel of Targeted Therapy, ACS Chemical Biology, 2015, 10, 5, 1319

    CrossRef

  4. 4
    Daniele Zampieri, Erik Laurini, Luciano Vio, Maurizio Fermeglia, Sabrina Pricl, Bernhard Wünsch, Dirk Schepmann, Maria Grazia Mamolo, Improving selectivity preserving affinity: New piperidine-4-carboxamide derivatives as effective sigma-1-ligands, European Journal of Medicinal Chemistry, 2015, 90, 797

    CrossRef

  5. 5
    Isidro Cortés-Ciriano, Qurrat Ul Ain, Vigneshwari Subramanian, Eelke B. Lenselink, Oscar Méndez-Lucio, Adriaan P. IJzerman, Gerd Wohlfahrt, Peteris Prusis, Thérèse E. Malliavin, Gerard J. P. van Westen, Andreas Bender, Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects, Med. Chem. Commun., 2015, 6, 1, 24

    CrossRef

  6. 6
    Tom D. Bunney, Shunzhou Wan, Nethaji Thiyagarajan, Ludovico Sutto, Sarah V. Williams, Paul Ashford, Hans Koss, Margaret A. Knowles, Francesco L. Gervasio, Peter V. Coveney, Matilda Katan, The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study, EBioMedicine, 2015, 2, 3, 194

    CrossRef

  7. 7
    Diwakar Shukla, Yilin Meng, Benoît Roux, Vijay S. Pande, Activation pathway of Src kinase reveals intermediate states as targets for drug design, Nature Communications, 2014, 5,

    CrossRef

  8. 8
    Michael S Mathisen, Hagop M Kantarjian, Elias J Jabbour, Emerging drugs for acute lymphocytic leukemia, Expert Opinion on Emerging Drugs, 2014, 19, 1, 37

    CrossRef

  9. 9
    Don L. Gibbons, Sabrina Pricl, Paola Posocco, Erik Laurini, Maurizio Fermeglia, Hanshi Sun, Moshe Talpaz, Nicholas Donato, Alfonso Quintás-Cardama, Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy, Proceedings of the National Academy of Sciences, 2014, 111, 9, 3550

    CrossRef

  10. 10
    Clive McCarthy, Edward Walker, Tropomyosin receptor kinase inhibitors: a patent update 2009 – 2013, Expert Opinion on Therapeutic Patents, 2014, 24, 7, 731

    CrossRef

  11. 11
    Erik Laurini, Valentina Da Col, Bernhard Wünsch, Sabrina Pricl, Analysis of the molecular interactions of the potent analgesic S1RA with the σ1 receptor, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 10, 2868

    CrossRef

  12. 12
    Frédéric Thomas, Daniel Fisher, Philippe Fort, Jean-Pierre Marie, Simon Daoust, Benjamin Roche, Christoph Grunau, Céline Cosseau, Guillaume Mitta, Stephen Baghdiguian, François Rousset, Patrice Lassus, Eric Assenat, Damien Grégoire, Dorothée Missé, Alexander Lorz, Frédérique Billy, William Vainchenker, François Delhommeau, Serge Koscielny, Raphael Itzykson, Ruoping Tang, Fanny Fava, Annabelle Ballesta, Thomas Lepoutre, Liliana Krasinska, Vjekoslav Dulic, Peggy Raynaud, Philippe Blache, Corinne Quittau-Prevostel, Emmanuel Vignal, Hélène Trauchessec, Benoit Perthame, Jean Clairambault, Vitali Volpert, Eric Solary, Urszula Hibner, Michael E. Hochberg, Applying ecological and evolutionary theory to cancer: a long and winding road, Evolutionary Applications, 2013, 6, 1
  13. 13
    Daniela Rossi, Alice Pedrali, Raffaella Gaggeri, Annamaria Marra, Luca Pignataro, Erik Laurini, Valentina Dal Col, Maurizio Fermeglia, Sabrina Pricl, Dirk Schepmann, Bernhard Wünsch, Marco Peviani, Daniela Curti, Simona Collina, Chemical, Pharmacological, and in vitro Metabolic Stability Studies on Enantiomerically Pure RC-33 Compounds: Promising Neuroprotective Agents Acting as σ1 Receptor Agonists, ChemMedChem, 2013, 8, 9
  14. 14
    Daniela Rossi, Annamaria Marra, Pietro Picconi, Massimo Serra, Laura Catenacci, Milena Sorrenti, Erik Laurini, Maurizio Fermeglia, Sabrina Pricl, Stefania Brambilla, Nicoletta Almirante, Marco Peviani, Daniela Curti, Simona Collina, Identification of RC-33 as a potent and selective σ1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-Scale synthesis, physicochemical characterization and in vitro metabolic stability, Bioorganic & Medicinal Chemistry, 2013, 21, 9, 2577

    CrossRef

  15. 15
    André Richters, Julia Ketzer, Matthäus Getlik, Christian Grütter, Ralf Schneider, Johannes M. Heuckmann, Stefanie Heynck, Martin L. Sos, Anu Gupta, Anke Unger, Carsten Schultz-Fademrecht, Roman K. Thomas, Sebastian Bauer, Daniel Rauh, Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design, Journal of Medicinal Chemistry, 2013, 56, 14, 5757

    CrossRef

  16. 16
    Sara A Byron, Huaibin Chen, Andreas Wortmann, David Loch, Michael G Gartside, Farhad Dehkhoda, Steven P Blais, Thomas A Neubert, Moosa Mohammadi, Pamela M Pollock, The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors, Neoplasia, 2013, 15, 8, 975

    CrossRef

  17. 17
    Erik Laurini, Paola Posocco, Maurizio Fermeglia, Don L. Gibbons, Alfonso Quintás-Cardama, Sabrina Pricl, Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments, Molecular Oncology, 2013, 7, 5, 968

    CrossRef

  18. 18
    Swen Hoelder, Paul A. Clarke, Paul Workman, Discovery of small molecule cancer drugs: Successes, challenges and opportunities, Molecular Oncology, 2012, 6, 2, 155

    CrossRef

  19. 19
    Linda Nichols, Julie Pippins, Lon Castle, Mary Cassler, Courtney Fuller, Molecular monitoring of chronic myeloid leukemia: a personalized approach to optimizing treatment response, Personalized Medicine, 2012, 9, 7, 727

    CrossRef

  20. 20
    Reinhard Dummer, Keith T. Flaherty, Resistance patterns with tyrosine kinase inhibitors in melanoma, Current Opinion in Oncology, 2012, 24, 2, 150

    CrossRef

  21. 21
    Anthony Oyekunle, Torsten Haferlach, Nicolaus Kröger, Evgeny Klyuchnikov, Axel Rolf Zander, Susanne Schnittger, Ulrike Bacher, Molecular Diagnostics, Targeted Therapy, and the Indication for Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia, Advances in Hematology, 2011, 2011, 1

    CrossRef